Details for New Drug Application (NDA): 003240
✉ Email this page to a colleague
NDA 003240 describes METANDREN, which is a drug marketed by Novartis and is included in one NDA. Additional details are available on the METANDREN profile page.
The generic ingredient in METANDREN is methyltestosterone. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methyltestosterone profile page.
The generic ingredient in METANDREN is methyltestosterone. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methyltestosterone profile page.
Summary for 003240
| Tradename: | METANDREN |
| Applicant: | Novartis |
| Ingredient: | methyltestosterone |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 003240
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;BUCCAL, SUBLINGUAL | Strength | 10MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;BUCCAL, SUBLINGUAL | Strength | 25MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 004
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;BUCCAL, SUBLINGUAL | Strength | 5MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
